Fausto Barbieri

Crizotinib in <i>MET</i> -Deregulated or <i>ROS1</i> -Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial

Lorenza Landi, Rita Chiari, Marcello Tiseo et al. · Clinical Cancer Research · 2019 · 186 citations · Full text

Medicine, Oncology, Pharmacology +16

Primary Lung Cancer Presenting with Gastrointestinal Tract Involvement: Clinicopathologic and Immunohistochemical Features in a Series of 18 Consecutive Cases

Giulio Rossi, Alessandro Marchioni, Elena Romagnani et al. · Journal of Thoracic Oncology · 2007 · 151 citations · Full text

Medicine, Oncology, Pathology +17

First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status

Francesco Facchinetti, Giulia Mazzaschi, Fausto Barbieri et al. · European Journal of Cancer · 2020 · 147 citations · Full text

Medicine, Oncology, Pharmacology +13

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

Alessio Cortellini, Massimo Di Maïo, Olga Nigro et al. · Journal for ImmunoTherapy of Cancer · 2021 · 144 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy

Roberta Minari, Paola Bordi, Marzia Del Re et al. · Lung Cancer · 2017 · 108 citations

Medicine, Pathology, Pharmacotherapy +11